Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple mechanisms downregulate CDKN1C in human bladder cancer.

Michèle J Hoffmann1, Andrea R Florl, Hans-Helge Seifert

  • 1Urologische Klinik, Heinrich-Heine-Universität, Düsseldorf, Germany.

International Journal of Cancer
|November 20, 2004
PubMed
Summary

Downregulation of the CDKN1C gene (cell cycle inhibitor p57KIP2) is common in advanced urothelial cancers. Multiple mechanisms, including LOH, promoter hypermethylation, and imprinting changes, contribute to its reduced expression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combining 5-ALA-PDT with berbamine as an in vitro multimodal therapy approach against bladder cancer cells.

Scientific reports·2026
Same author

[Report from the 16th annual meeting of the DFBK, 16-17th January 2026 in Ulm].

Urologie (Heidelberg, Germany)·2026
Same author

Impact of a robotic-assisted transperineal biopsy platform on pathologic upgrading and downgrading at prostatectomy.

World journal of urology·2026
Same author

Introduction of a Structured Reporting Protocol and Surgical Checklist for Rezum Water Vapor Therapy (VAPOR-SRP).

Journal of clinical medicine·2025
Same author

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107.

Molecular oncology·2025
Same author

Single-dose Versus 3-day Antimicrobial Prophylaxis in Transurethral Resection or Photoselective Vaporization of the Prostate: A Multicenter, Randomized, Placebo Controlled Trial (CITrUS Trial).

European urology focus·2025

Area of Science:

  • Oncology
  • Genetics
  • Epigenetics

Background:

  • The CDKN1C gene, encoding the cell cycle inhibitor p57KIP2, is imprinted and located at chromosome 11p15.5.
  • Disturbed CDKN1C expression is implicated in Beckwith-Wiedemann syndrome and various human cancers.
  • Downregulation of CDKN1C is frequently observed in advanced urothelial cancers (TCC).

Purpose of the Study:

  • To investigate the mechanisms responsible for CDKN1C downregulation in TCC.
  • To compare CDKN1C expression in TCC cell lines with normal urothelial cells (UEC).

Main Methods:

  • Analysis of CDKN1C mRNA and p57KIP2 protein expression in TCC cell lines and UEC.
  • Investigation of Loss of Heterozygosity (LOH) at 11p15.5 using polymorphic markers.
  • Bisulfite sequencing to assess CDKN1C promoter methylation.

Related Experiment Videos

  • Treatment with the methylation inhibitor 5-aza-2'deoxycytidine.
  • Analysis of imprinting center 2 (IC2) differentially methylated regions (DMRs) and LIT1 RNA expression.

    • Main Results:

    • CDKN1C mRNA and p57KIP2 protein were diminished in 12/15 TCC lines.
    • LOH at 11p15.5 was identified in 3 cell lines.
    • CDKN1C promoter hypermethylation was detected in several TCC lines, correlating with downregulation in at least one.
    • 5-aza-2'deoxycytidine treatment induced CDKN1C expression.
    • IC2 hypomethylation, associated with LIT1 re-expression, was found in most TCC lines, correlating with CDKN1C downregulation in several.

    Conclusions:

    • CDKN1C downregulation in TCC occurs through multiple distinct mechanisms.
    • These mechanisms include LOH, promoter hypermethylation, and altered imprinting.
    • Given its tumor suppressor potential (p57KIP2 induces senescence), CDKN1C is a promising candidate for 11p tumor suppression in TCC.